Asthma

54 trials 18 recruiting MedDRA PT
54 Registered trials
18 Recruiting
22 Unique sponsors
40 Unique IMPs
49 Commercial trials
Drug classes (ATC)
— ATC code not specified 34
R Respiratory (ATC R) 18
D Dermatology (ATC D) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 30 substances
Monoclonal antibody 4 substances
Monoclonal antibody (immune) 2 substances
Monoclonal antibody (immune, humanized) 2 substances
JAK inhibitor 1 substance
Corticosteroid 1 substance
Phase III: 18 Phase II: 15 Phase I/II: 2 Phase IV: 7 Phase I: 4 Phase I (Other): 6 Other: 2

Filter these 54 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 54 trials

Phase III

18 trials
  • AstraZeneca AB Commercial
    BENRALIZUMAB
    2022-501344-14-00 5 countries 2023 n=72
    Recruiting
  • AstraZeneca AB Commercial
    IMP not specified
    2022-502984-39-00 7 countries 2023 n=45
    Recruiting
  • AstraZeneca AB Commercial
    TEZEPELUMAB
    2023-504648-33-00 2 countries 2022 n=76
    Ended
  • AstraZeneca AB Commercial
    BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE; BUDESONIDE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE; FORMOTEROL FUMARATE, BUDESONIDE; FORMOTEROL FUMARATE, BUDESONIDE, GLYCOPYRRONIUM BROMIDE
    2023-505786-88-00 5 countries 2021 n=441
    Ended
  • AstraZeneca AB Commercial
    BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE; BUDESONIDE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE; FORMOTEROL FUMARATE, BUDESONIDE; FORMOTEROL FUMARATE, BUDESONIDE, GLYCOPYRRONIUM BROMIDE
    2023-505787-11-00 6 countries 2021 n=678
    Ended
  • AstraZeneca AB Commercial
    TEZEPELUMAB
    2024-512113-41-00 7 countries 2024 n=152
    Recruiting
  • AstraZeneca AB Commercial
    BUDESONIDE; BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE; FORMOTEROL FUMARATE, BUDESONIDE
    2024-513568-24-00 3 countries 2022 n=160
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS
    2023-503333-22-00 11 countries 2024 n=677
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    FLUTICASONE PROPIONATE, SALMETEROL; GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS
    2024-514248-95-00 3 countries n=147
    Pending
  • Generate Biomedicines Inc. Commercial
    GB-0895
    2025-521950-41-00 10 countries n=271
    Pending
  • Generate Biomedicines Inc. Commercial
    GB-0895
    2025-524040-35-00 6 countries n=73
    Pending
  • Glaxosmithkline Research & Development Limited Commercial
    BENRALIZUMAB; DEPEMOKIMAB; MEPOLIZUMAB
    2023-510230-84-00 12 countries 2021 n=750
    Ended
  • Novartis Pharma AG Commercial
    BUDESONIDE; MOMETASONE FUROATE, INDACATEROL ACETATE
    2022-501899-26-00 9 countries 2023 n=94
    Recruiting
  • Sandoz Private Limited Commercial
    FLUTICASONE FUROATE, VILANTEROL; SALBUTAMOL SULFATE
    2025-521565-27-00 1 country n=120
    Not authorised
  • Sanofi-Aventis Research & Development Commercial
    DUPILUMAB
    2023-504331-41-00 9 countries 2024 n=69
    Ended
  • Teva Branded Pharmaceutical Products R&D LLC Commercial
    FLUTICASONE PROPIONATE, SALBUTAMOL SULFATE; SALBUTAMOL SULFATE
    2023-505435-12-00 12 countries 2024 n=1,000
    Ended
  • Teva Branded Pharmaceutical Products R&D LLC Commercial
    FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE, SALBUTAMOL SULFATE; SALBUTAMOL SULFATE
    2024-517991-39-00 6 countries 2025 n=555
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    TEZEPELUMAB
    2024-513195-18-00 1 country 2023 n=150
    Recruiting

Phase II

15 trials
  • Amgen Inc. Commercial
    ROCATINLIMAB
    2023-508039-29-00 5 countries 2024 n=110
    Ended
  • AstraZeneca AB Commercial
    ATULIFLAPON
    2023-509243-27-00 10 countries 2023 n=431
    Ended
  • AstraZeneca AB Commercial
    TOZORAKIMAB
    2024-519116-14-00 5 countries 2025 n=70
    Recruiting
  • Chiesi Farmaceutici S.p.A. Commercial
    TANIMILAST
    2022-502208-64-00 10 countries 2023 n=377
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    TANIMILAST
    2024-516483-29-00 1 country 2025 n=50
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE; GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS; PLACEBO
    2025-521456-35-00 8 countries 2026 n=250
    Recruiting
  • Glaxosmithkline Research & Development Limited Commercial
    GSK5784283
    2024-518321-15-00 5 countries 2025 n=136
    Ended
  • Incyte Corp. Commercial
    4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]-2,5-DIFLUORO-N-[(2S)-1,1,1-TRIFLUOROPROPAN-2-YL]BENZAMIDE; POVORCITINIB
    2022-502570-16-01 3 countries 2024 n=84
    Recruiting
  • Novartis Pharma AG Commercial
    GLYCOPYRRONIUM BROMIDE
    2024-511382-11-00 4 countries 2022 n=30
    Recruiting
  • Pfizer Inc. Commercial
    IMP not specified
    2024-517866-40-00 7 countries 2025 n=90
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    AMLITELIMAB
    2023-503385-24-00 3 countries 2024 n=88
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    AMLITELIMAB
    2024-510641-33-00 3 countries 2023 n=104
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    LUNSEKIMIG
    2024-513959-33-00 10 countries 2025 n=673
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2025-522896-27-00 9 countries 2026 n=90
    Recruiting
  • Windward Bio AG Commercial
    HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST TSLP
    2025-521391-58-00 5 countries 2025 n=153
    Recruiting

Phase I/II

2 trials
  • Arrowhead Pharmaceuticals Inc. Commercial
    ADS-015
    2023-509654-60-00 2 countries 2023 n=42
    Ended
  • Arrowhead Pharmaceuticals Inc. Commercial
    ADS-013
    2024-514809-67-00 2 countries 2023 n=32
    Ended

Phase IV

7 trials
  • Chiesi Farmaceutici S.p.A. Commercial
    BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE; FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS
    2025-524289-56-00 8 countries n=606
    Pending
  • Regeneron Pharmaceuticals Inc. Commercial
    DUPILUMAB; FLUTICASONE PROPIONATE, SALMETEROL
    2023-510458-18-00 3 countries 2025 n=62
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    DUPILUMAB
    2024-513423-16-00 7 countries 2022 n=506
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    BENRALIZUMAB
    2024-514843-27-00 1 country 2021 n=220
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    DUPILUMAB
    2024-516789-13-00 1 country 2025 n=205
    Recruiting
  • Cliniques Universitaires Saint-Luc Academic
    IMP not specified
    2024-516783-29-00 2 countries 2018 n=340
    Ended
  • Hospices Civils De Lyon Academic
    BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE; FLUTICASONE FUROATE, VILANTEROL; FLUTICASONE PROPIONATE, SALMETEROL; FORMOTEROL FUMARATE DIHYDRATE; FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS; MEPOLIZUMAB; MOMETASONE FUROATE, GLYCOPYRRONIUM BROMIDE, INDACATEROL; TIOTROPIUM; TIOTROPIUM BROMIDE MONOHYDRATE; UMECLIDINIUM BROMIDE
    2022-501029-19-00 1 country 2022 n=130
    Ended

Phase I

4 trials
  • Amgen Inc. Commercial
    IMP not specified
    2025-520503-27-00 1 country 2025 n=3
    Ended
  • Bambusa Therapeutics Inc. Commercial
    IMP not specified
    2025-523142-28-00 1 country n=36
    Pending
  • Generate Biomedicines Inc. Commercial
    IMP not specified
    2023-507611-35-00 1 country 2024 n=70
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-517644-62-00 2 countries 2025 n=46
    Recruiting

Phase I (Other)

6 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2024-514213-35-00 1 country 2025 n=24
    Ended
  • AstraZeneca AB Commercial
    IMP not specified
    2024-516474-30-00 1 country 2025 n=16
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    IMP not specified
    2023-504326-19-00 1 country 2023 n=71
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-504304-29-00 3 countries 2024 n=30
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    IMP not specified
    2023-508279-36-00 1 country 2024 n=60
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2023-509316-28-00 1 country 2024 n=128
    Ended

Other

2 trials
  • Respirent Pharmaceuticals Co. Ltd. Commercial
    IMP not specified
    2023-504789-48-00 1 country 2023 n=34
    Ended
  • Respirent Pharmaceuticals Co. Ltd. Commercial
    IMP not specified
    2023-505198-34-00 1 country 2023 n=34
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 11 Phase I (Other), Phase II, Phase III 4
Chiesi Farmaceutici S.p.A. Commercial 7 Phase I (Other), Phase II, Phase III, Phase IV 1
Sanofi-Aventis Recherche & Developpement Commercial 6 Phase I (Other), Phase II, Phase IV 2
Generate Biomedicines Inc. Commercial 3 Phase I, Phase III 1
Glaxosmithkline Research & Development Limited Commercial 3 Phase I (Other), Phase II, Phase III 0
Centre Hospitalier Universitaire De Nantes Academic 3 Phase III, Phase IV 3
Amgen Inc. Commercial 2 Phase I, Phase II 0
Respirent Pharmaceuticals Co. Ltd. Commercial 2 Other 0
Novartis Pharma AG Commercial 2 Phase II, Phase III 2
Teva Branded Pharmaceutical Products R&D LLC Commercial 2 Phase III 1
Arrowhead Pharmaceuticals Inc. Commercial 2 Phase I/II 0
Bambusa Therapeutics Inc. Commercial 1 Phase I 0
Janssen - Cilag International Commercial 1 Phase I 1
F. Hoffmann-La Roche AG Commercial 1 Phase I (Other) 0
Incyte Corp. Commercial 1 Phase II 1
Pfizer Inc. Commercial 1 Phase II 1
Windward Bio AG Commercial 1 Phase II 1
Sandoz Private Limited Commercial 1 Phase III 0
Sanofi-Aventis Research & Development Commercial 1 Phase III 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase IV 0
New trials by year
2021
4
2022
5
2023
12
2024
11
2025
13
2026
2
← All indication landscapes